A Randomised three arm, open-label, Phase II study of continuous Selumetinib versus continuous or interrupted Selumetinib in combination with weekly Paclitaxel in metastatic Uveal Melanoma

Trial Profile

A Randomised three arm, open-label, Phase II study of continuous Selumetinib versus continuous or interrupted Selumetinib in combination with weekly Paclitaxel in metastatic Uveal Melanoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Selumetinib (Primary)
  • Indications Uveal melanoma
  • Focus Therapeutic Use
  • Acronyms SelPac Version 1
  • Most Recent Events

    • 11 Feb 2016 Accrual to date is 4% according to United Kingdom Clinical Research Network record.
    • 16 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top